Indian Firms May Want To Slow March Into China
New markets are opening up for Indian firms and China appears to be the flavor of the season, but gaining a strong foothold there is not expected to be even "half as easy" as in the US.
You may also be interested in...
India revises foreign direct investment rules to bridle any attempts at opportunistic M&A amid the COVID-19 crisis. The move is seen largely targeted at China, though pharma experts have mixed views on the new screening measures.
Scrip traces some of the prominent changes in the corner office at front-line, family-owned Indian firms Cipla and Dr Reddy’s in the decade gone by.
Dr Reddy’s sees its Indian domestic market and China as hot prospects as it pursues its “transformation journey” in which it is reducing its dependence on the slowing US market.